GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Utah Medical Products Inc (NAS:UTMD) » Definitions » Change In Receivables

Utah Medical Products (Utah Medical Products) Change In Receivables : $2.27 Mil (TTM As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Utah Medical Products Change In Receivables?

Utah Medical Products's change in receivables for the quarter that ended in Dec. 2023 was $0.14 Mil. It means Utah Medical Products's Accounts Receivable declined by $0.14 Mil from Sep. 2023 to Dec. 2023 .

Utah Medical Products's change in receivables for the fiscal year that ended in Dec. 2023 was $2.27 Mil. It means Utah Medical Products's Accounts Receivable declined by $2.27 Mil from Dec. 2022 to Dec. 2023 .

Utah Medical Products's Accounts Receivable for the quarter that ended in Dec. 2023 was $3.49 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Utah Medical Products's Days Sales Outstanding for the three months ended in Dec. 2023 was 25.81.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Utah Medical Products's liquidation value for the three months ended in Dec. 2023 was $93.13 Mil.


Utah Medical Products Change In Receivables Historical Data

The historical data trend for Utah Medical Products's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Utah Medical Products Change In Receivables Chart

Utah Medical Products Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.75 0.66 -1.13 -0.53 2.27

Utah Medical Products Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 1.79 0.26 0.09 0.14

Utah Medical Products Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Utah Medical Products  (NAS:UTMD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Utah Medical Products's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3.488/12.333*91
=25.81

2. In Ben Graham's calculation of liquidation value, Utah Medical Products's accounts receivable are only considered to be worth 75% of book value:

Utah Medical Products's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=92.868-7.145+0.75 * 3.488+0.5 * 9.582
=93.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Utah Medical Products Change In Receivables Related Terms

Thank you for viewing the detailed overview of Utah Medical Products's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Utah Medical Products (Utah Medical Products) Business Description

Traded in Other Exchanges
Address
7043 South 300 West, Midvale, UT, USA, 84047
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals as well as outpatient clinics and physicians offices.
Executives
Paul O Richins director, officer: VP, Treasurer, Asst. Secretary 7043 SOUTH 300 WEST, MIDVALE UT 84047
Barbara A Payne director
Ernst G Hoyer director
Kevin L Cornwell director, officer: Chairman, CEO, Secretary
Brian Koopman officer: Principal Financial Officer 108 E 1700 S, BOUNTIFUL UT 84010
James H Beeson director 7043 SOUTH 300 WEST, MIDVALE UT 84047
Greg A Leclaire officer: Chief Financial Officer 5225 WILEY POST WAY, SUITE 500, SALT LAKE CITY UT 84116
Stephen W Bennett director